跳至主要内容
临床试验/NCT05966350
NCT05966350已完成不适用

Anti-Argonaute Antibodies for the Diagnosis of Sensory Neuronopathies

Centre Hospitalier Universitaire de Saint Etienne1 个研究点 分布在 1 个国家目标入组 630 人开始时间: 2021年5月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
630
试验地点
1
主要终点
Sensitivity-specificity of Argonaute (AGO) antibodies for the diagnosis of sensory neuronopathies

研究概览

简要总结

Argonaute (AGO) proteins have been described as the target of antibodies in several autoimmune diseases including Sjögren Syndrome (SS). Sensory neuronopathies (SNN) are disorders affecting neurons in the dorsal root ganglia that may depend on an inflammatory process. However, identifying these cases needs the availability of specific biomarkers. The aim of this study is to test the prevalence of anti-AGO antibodies in a population of patients with Sensory neuronopathies (SNN) with and without associated autoimmune disease in comparison with other peripheral neuropathies to determine how anti-AGO antibodies may help the identification of potentially dysimmune Sensory neuronopathies (SNN).

详细描述

Sensory neuronopathies (SNN) are rare and debilitating diseases that fall under several etiologies. Among them, dysimmune forms are the most frequent but very difficult to identify when they do not occur in the context of associated systemic dysimmune disease (Sjögren Syndrome (SS) syndrome) because only a biopsy of the epiphytically unthinkable posterior spinal node would support the diagnosis. It is therefore necessary to have diagnostic biological markers of these forms to consider rapid treatment before irreversible neuronal degeneration.Using a protein-array technique, it has been showed that anti-FGFR3 antibodies was one of these markers and that it was associated with a clinical picture that differentiated from Sensory neuronopathies (SNN) without this antibody. Protein-array also allowed to identify another potentially interesting antibody for the diagnosis of Sensitive neuronopathies (NNS). This antibody recognizes the AGO1 protein. Anti-AGO1 antibodies have been described in association with system autoimmune diseases and in particular lupus but not in neurological diseases and more particularly in Sensory neuronopathies (SNN). The study want to validate the diagnostic interest of these antibodies by testing the collection of serums performed for studies on the anti-FGFR3 antibody and including patients with Sensory neuronopathies (SNN) and as controls of patients with another form of neuropathy and subjects with systemic autoimmune disease without peripheral neuropathy.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with sensory neuropathy

排除标准

  • Patient not tested for anti-AGO antibody

结局指标

主要结局

Sensitivity-specificity of Argonaute (AGO) antibodies for the diagnosis of sensory neuronopathies

时间窗: 2 Years

Sensitivity-specificity of Argonaute (AGO) antibodies screening

次要结局

  • Comparison of data between patients with anti-AGO antibodies versus patients without anti-AGO antibodies(2 Years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验